In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altana Inc.

Division of Altana AG

Latest From Altana Inc.

Will Pharma Split Spur Altana Into Action?

Altana AG announced in July that it would split out the pharmaceuticals division into a separately listed company sometime next year. The news followed a large acquisition in chemicals; but for pharma, the timing couldn't have been worse. Two key late-stage development projects suffered setbacks in the last 12 months, and there's little in the pipeline to replace them.
BioPharmaceutical Strategy

Dealmaking (09/02)

Summarizing the month in European dealmaking.

Altana Calls Trumps

The success of gastrointestinal drug pantoprazole has turned mid-sized Altana into one of Europe's fastest growing pharmaceutical companies. By re-investing the proceeds from pantoprazole into its own R&D, Altana now has two late-stage follow-ons--ciclesonide and roflumilast--with similar potential to pantoprazole. Rather than simply out-licensing these compounds to larger players, Altana wants a more active role alongside its partners in marketing and selling its own drugs, hoping thereby to establish itself internationally.
BioPharmaceutical Strategy

Elusys Therapeutics

The core technology on which EluSys Therapeutics is based is a bispecific antibody technology with broad potential to bind to and clear toxins, auto-antibodies, and pathogens. That technology, called the HP System, is based on the mechanism of immune adherence. In response to a foreign substance (an antigen) entering the bloodstream, the immune system produces antibodies that bind the antigen, forming an immune complex, which in turn activates the complement system. A complement protein attaches to the immune complex and binds to the CR1 receptor of the complement system, which is found on all red blood cells (RBCs). The bound immune complex is then transported to the liver, where it is stripped off the RBC and destroyed by macrophages. Taylor's invention uses a heteropolymer-an antibody specific for both the CR1 receptor and the target antigen-to clear the target antigen without having to activate the complement system, which improves the efficiency of the clearance process.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Altana AG
  • Senior Management
  • George Kole, Pres.
    Robert Cetrullo, PhD, VP, Bus. Dev.
    Tushar P Shah, MD, SVP, Scientific & Clin. Affairs
  • Contact Info
  • Altana Inc.
    Phone: (516) 454-7677
    60 Baylis Rd.
    Melville, NY 11747